Genome Editing Human Neural Stem Cells Safe Harbor Insertion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies, such as the CRISPR/Cas system, are inefficient for modifying primary cells like human neural stem cells, necessitating the development of more effective methods for genetic modification.
Innovation Solution
A method involving the introduction of a donor template with a transgene cassette and a DNA nuclease into human neural stem cells to create double-strand breaks in a safe harbor gene, facilitating the insertion of the transgene and enhancing genome editing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CRISPR/Cas system is used for genome editing in human neural stem cells, then the technology can modify genomic sequences, but the editing efficiency remains inefficient
Solution Approach 1:
The patent changes key parameters of the CRISPR/Cas system by using modified Cas9 nucleases (such as Cas9-HQ, Cas9-J, or Cas9-K) with altered PAM recognition specificity, and by optimizing sgRNA design and delivery methods. These parameter modifications enable more efficient and reliable genome editing in human neural stem cells while maintaining safety.
Solution Approach 2:
The patent introduces an intermediary mechanism by using a donor template with homology arms that facilitates homology-directed repair (HDR) as an intermediate step between DNA cleavage and final genome modification. This intermediary HDR process significantly improves editing efficiency and reliability in neural stem cells.
2Adaptability or versatility
If genome editing is performed in primary cells like human neural stem cells, then therapeutic applications become possible, but the editing efficiency remains low
Solution Approach 1:
The patent applies preliminary action by pre-designing and pre-optimizing the donor template with specific homology arms and transgene cassettes before the actual editing process. The CRISPR components are also pre-optimized for neural stem cell specificity. This preliminary preparation enables efficient editing when applied to primary cells, unlocking therapeutic potential.
Solution Approach 2:
The patent modifies critical parameters including nuclease specificity, PAM recognition rules, sgRNA sequences, and delivery timing to match the unique characteristics of human neural stem cells. These parameter optimizations enable efficient editing in primary cells while maintaining their therapeutic applicability.
3Manufacturing precision
If conventional nuclease techniques are used for genome editing, then site-specific double-strand breaks can be generated, but the overall editing efficiency is insufficient
Solution Approach 1:
The patent changes the parameters of the nuclease system by using modified Cas9 variants with altered PAM recognition specificities and optimized cutting kinetics. These parameter changes enable the system to achieve both high site-specific accuracy and increased editing frequency simultaneously in human neural stem cells.
Solution Approach 2:
The patent ensures continuity of useful action by using donor templates that continuously provide homology-directed repair guidance, and by employing nuclease systems that maintain controlled, continuous cutting activity. This continuous action improves both the accuracy and frequency of site-specific editing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the frequency of gene editing in human neural stem cells, allowing for the generation of genetically modified cells that retain their stem cell characteristics and potential therapeutic applications for neurodegenerative diseases.
Implementation Method 1
a DNA nuclease or a nucleotide sequence encoding the DNA nuclease, wherein the DNA nuclease is capable of creating a double-strand break in the safe harbor gene to induce insertion of the transgene into the safe harbor gene
Implementation Method 2
two nucleotide sequences comprising two non-overlapping, homologous portions of a safe harbor gene, wherein the nucleotide sequences are located at the 5' and 3' ends of the transgene cassette
Data Source
AI summary
The invention provides methods for generating a genetically modified human neural stem cell, genetically modified human neural stem cells, and pharmaceutical compositions comprising the genetically modified human neural stem cells. Also provided are associated kits. The invention also provides methods for preventing or treating a neurodegenerative disease or a neurological injury in a human subject using genetically modified human neural stem cells.